Intellia Therapeutics, Inc.
NTLA
$7.25
-$1.19-14.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 2.47% | -11.04% | -18.83% | -4.18% | -16.54% |
| Total Depreciation and Amortization | 4.06% | 13.89% | 19.77% | 22.54% | 21.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.60% | 18.86% | 56.42% | -51.16% | -3.99% |
| Change in Net Operating Assets | -34.41% | 172.61% | 695.46% | 19.43% | 123.18% |
| Cash from Operations | 8.45% | 16.32% | 35.58% | -10.37% | -3.54% |
| Capital Expenditure | 35.46% | 70.48% | 76.47% | 34.60% | 61.15% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 221.43% | -107.67% | 23.35% | 107.10% | 280.87% |
| Cash from Investing | 229.93% | -109.70% | 29.96% | 104.83% | 252.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.82% | 330.28% | 1,539.35% | 2,601.13% | -78.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -97.82% | 330.28% | 1,539.35% | 2,601.13% | -78.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 15.70% | -272.58% | 66.38% | 76.12% | -84.61% |